Lupus (SLE): vizsgálatok itt: Olaszország
26 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Where
- Ancona, Caserta, Ferrara, Milan, Naples, Padova, Pisa, Rome, Turin
- Életkor
- 12 év to 100 év
- People
- 550 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00 - 1. fázisTaking peopleTo Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- Where
- Brescia, Rome, Rozzano
- Életkor
- 18 év to 75 év
- People
- 46 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Where
- Florence, Genoa, Milan, Rome, Rozzano
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Where
- Catania, Modena, Rome, Verona
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Where
- Genoa, Milan, Rome
- Életkor
- 5 év to 17 év
- People
- 40 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00 - 3. fázisTaking peopleA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Where
- Ancona, Catania, Milan, Perugia, Rome, Rozzano, Turin, Udine, Verona
- Életkor
- 18 év to 75 év
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- Brescia, Genoa, Milan, Modena, Monza, Padova, Pisa, Rome, Rozzano, Udine
- Életkor
- 16 év and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - No phaseTaking peopleA Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Where
- Brescia, Ferrara, Padova, Torino
- Életkor
- 16 év and over
- People
- 223 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07175285 - 1. fázisTaking peopleA Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
- Where
- Rome, Rozzano
- Életkor
- 18 év to 75 év
- People
- 21 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07363590 · EU 2025-523412-36-00 - 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Brescia, Catania, Cona, Florence, Milan, Pavia, Roma
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisNot yet taking people in OlaszországRollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
- Where
- Brescia, Ferrara, Florence, Milan, Rome
- People
- 340 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00 - 2. fázisTaking peopleA Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- Where
- Brescia, Rome, Rozzano, Turin
- Életkor
- 18 év and over
- People
- 30 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07598396 · EU 2024-519930-22-00 - 3. fázisCsak meghívásosA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- Brescia, Catania, Ferrara, Genoa, Milan, Modena, Monza, Padova, Pisa, Rome, Rozzano, Udine
- Életkor
- 16 év and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - 1. fázisNot yet taking people in OlaszországA study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
- Where
- DO NOT EDIT
- Életkor
- Up to 64 év
- People
- 10 worldwide
- Run by
- UCB Biopharma
See details and how to join2025-524595-37-00 · EU 2025-524595-37-00 - 3. fázisCsak meghívásosA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Rome
- Életkor
- 18 év and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00 - 2. fázisTaking peopleA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- Where
- Milan, Rozzano, Turin
- Életkor
- 18 év to 75 év
- People
- 220 worldwide
- Run by
- Amgen
See details and how to joinNCT06570798 - 3. fázisTaking peopleA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Where
- Brescia, Catania, Ferrara, Florence, Milan, Padova, Pisa, Rome, Rozzano, Udine
- Életkor
- 18 év and over
- People
- 113 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-523670-17-00 · EU 2025-523670-17-00 - 3. fázisTaking peopleAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Where
- Florence, Genoa, Milan, Padova, Rome
- Életkor
- 5 év to 17 év
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00 - 1. fázisNot yet taking people in OlaszországBasket trial for B-cEll driven severe auToimmunE and aLoimmune diseases (chronic Graft vErsUs host diseaSe) treated with anti-CD19 CAR T-cell thErapy
- Where
- Bologna, Rome
- People
- 24
- Run by
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
See details and how to join2025-522821-37-00 · EU 2025-522821-37-00 - 3. fázisTaking peopleA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Where
- Brescia, Catania, Ferrara, Florence, Milan, Padova, Pisa, Roma, Rozzano, Udine
- Életkor
- 18 év to 70 év
- People
- 245 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07430306 - 3. fázisTaking peopleEfficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
- Where
- Pisa, Verona
- Életkor
- 18 év and over
- People
- 147 worldwide
- Run by
- Bristol-Myers Squibb Services Unlimited Company
See details and how to join2022-500699-76-00 · EU 2022-500699-76-00 - No phaseTaking peopleAchievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
- Where
- Ancona, Bari, Brescia, Cona, Florence, Milan, Modena, Monserrato, Naples, Padova, Palermo, Pavia, Pisa, Roma, Rozzano, San Giovanni Rotondo, Torino, Trieste, Udine, Verona
- People
- 218
- Run by
- AstraZeneca
See details and how to joinNCT07330245 - No phaseTaking peopleStudy to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
- Where
- Rozzano
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06527872 - 1. fázisTaking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Ferrara, Rozzano
- Életkor
- 18 év to 70 év
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00 - 4. fázisTaking peopleSteroid withdrawal in SLE
- Where
- Brescia, Cagliari, Ferrara, Milan, Pisa
- Életkor
- 18 év and over
- People
- 252
- Run by
- Azienda Ospedaliero Universitaria Pisana
See details and how to join2024-518580-35-00 · EU 2024-518580-35-00